

Michael Frumovitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2782716/publications.pdf>

Version: 2024-02-01

144
papers

8,098
citations

53794

45
h-index

53230

85
g-index

149
all docs

149
docs citations

149
times ranked

6711
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study. <i>Gynecologic Oncology</i> , 2022, 165, 530-537.	1.4	5
2	Lymphatic Mapping and Sentinel Node Biopsy in High-Grade Uterine Cancers. <i>Current Oncology Reports</i> , 2022, 24, 1521-1529.	4.0	4
3	A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. <i>Supportive Care in Cancer</i> , 2021, 29, 213-222.	2.2	2
4	Fertility considerations prior to conservative management of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 339-344.	2.5	8
5	Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 495-501.	2.5	9
6	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 647-655.	2.5	28
7	An Integrated Approach to Selecting a Prepared Medical Decision-Maker. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 1305-1310.	1.2	2
8	Comparison of Internal Patient Satisfaction Scores at a Cancer Center With Star Ratings on Online Physician-Rating Websites. <i>JCO Oncology Practice</i> , 2021, 17, e1181-e1188.	2.9	2
9	Early-stage, high-grade neuroendocrine cervical carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1179-1183.	2.5	0
10	ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1317-1325.	2.5	79
11	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capiwasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6354-6365.	7.0	31
12	Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 249.e1-249.e10.	1.3	78
13	Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). <i>Gynecologic Oncology</i> , 2020, 157, 161-166.	1.4	106
14	Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 352-357.	2.5	8
15	PARP and PD-L1 as Potential Therapeutic Targets for Women with Neuroendocrine Cervical Cancer. <i>Gynecologic Oncology</i> , 2020, 156, e21-e22.	1.4	2
16	Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1303-1307.	2.5	26
17	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. <i>Journal of Cancer Education</i> , 2020, , 1.	1.3	1
18	Coronavirus (<sc>COVID</sc>â€19): Patient experienceâ€Administrative servicesâ€on the frontline during crisis. <i>Head and Neck</i> , 2020, 42, 1477-1481.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2020, 21, 851-860.	10.7	57
20	Successful pregnancy following chemotherapy in a survivor of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): A case report and review of literature. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100576.	0.6	2
21	Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. <i>Gynecologic Oncology</i> , 2020, 158, 570-575.	1.4	43
22	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. <i>PLoS ONE</i> , 2020, 15, e0234505.	2.5	25
23	Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer. <i>JAMA Oncology</i> , 2020, 6, 1019.	7.1	124
24	Phase II evaluation of copanlisib, a selective inhibitor of PI3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). <i>Gynecologic Oncology Reports</i> , 2020, 31, 100532.	0.6	9
25	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
26	Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 873-878.	2.5	42
27	COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 561-563.	2.5	137
28	IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 670-683.	2.5	18
29	Encouraging worldwide adoption of sentinel lymph node biopsies for gynecologic malignancies. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 281-282.	2.5	1
30	Surgical staging, the meaning of life, and other existential ponderings. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1862-1863.	2.5	4
31	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
32	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
33	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
34	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
35	Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 727-732.	0.6	6
36	Updates and management algorithm for neuroendocrine tumors of the uterine cervix. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 986-995.	2.5	71

#	ARTICLE	IF	CITATIONS
37	Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. <i>Cancer</i> , 2019, 125, 3347-3353.	4.1	12
38	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. <i>Oncotarget</i> , 2019, 10, 3533-3546.	1.8	19
39	Reproductive counseling and pregnancy outcomes after radical trachelectomy for early stage cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e45.	2.2	37
40	Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. <i>Obstetrics and Gynecology</i> , 2019, 134, 1253-1259.	2.4	19
41	Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. <i>Gynecologic Oncology</i> , 2019, 152, 101-105.	1.4	18
42	<i>PRKRA</i> /PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 162-172.	4.1	23
43	Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 87-93.	0.6	18
44	Radical parametrectomy after "cut-through" hysterectomy in low-risk early-stage cervical cancer: Time to consider this procedure obsolete. <i>Gynecologic Oncology</i> , 2018, 149, 520-524.	1.4	7
45	Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. <i>Gynecologic Oncology</i> , 2018, 148, 474-479.	1.4	24
46	Radical Hysterectomy and Age: Outcomes Comparison Based on a Minimally Invasive vs an Open Approach. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 1224-1230.	0.6	16
47	Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. <i>Gynecologic Oncology</i> , 2018, 148, 132-138.	1.4	53
48	Tailoring adjuvant treatment in patients with uterine cancer " Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e656.	10.7	1
49	The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e68.	2.2	9
50	Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 2102.	4.8	33
51	Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1895-1904.	27.0	1,274
52	Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 (≤2cm) cervical cancer: Bridging the gap to fetal viability. <i>Gynecologic Oncology</i> , 2018, 150, 50-55.	1.4	10
53	Imaging and staging of neuroendocrine cervical cancer. <i>Abdominal Radiology</i> , 2018, 43, 3468-3478.	2.1	16
54	Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. <i>Lancet Oncology</i> , The, 2018, 19, 1394-1403.	10.7	229

#	ARTICLE	IF	CITATIONS
55	Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2017, 145, 96-101.	1.4	143
56	Sentinel lymph node mapping in minimally invasive surgery: Role of imaging with color-segmented fluorescence (CSF). <i>Gynecologic Oncology</i> , 2017, 146, 676-677.	1.4	8
57	A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 146, 234-239.	1.4	171
58	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2093-2104.	7.0	48
59	Sentinel Lymph Node Biopsy for Cervical Cancer Patients â€œ Whatâ€™s It Gonna Take?. <i>Gynecologic Oncology</i> , 2017, 144, 3-4.	1.4	6
60	Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 546-553.	0.8	48
61	Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2017, 144, 46-50.	1.4	49
62	Mucinous Carcinoma of the Ovary. , 2017, , 221-232.		0
63	Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. <i>Gynecologic Oncology</i> , 2016, 141, 588-591.	1.4	53
64	Patterns of recurrence and survival in neuroendocrine cervical cancer. <i>Gynecologic Oncology</i> , 2016, 143, 552-557.	1.4	35
65	Utility of indocyanine green (ICG) intra-operative angiography to determine uterine vascular perfusion at the time of radical trachelectomy. <i>Gynecologic Oncology</i> , 2016, 143, 357-361.	1.4	25
66	Feasibility of a reduced field-of-view diffusion-weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 316-324.	3.4	27
67	Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer. <i>Gynecologic Oncology</i> , 2016, 142, 283-285.	1.4	11
68	Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 186-193.	0.6	47
69	Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 599-604.	0.9	31
70	Role of Minimally Invasive Surgery in Gynecologic Oncology: An Updated Survey of Members of the Society of Gynecologic Oncology. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1121-1127.	2.5	117
71	Make New Friends But Keep the Old: Minimally Invasive Surgery Training in Gynecologic Oncology Fellowship Programs. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1115-1120.	2.5	12
72	Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. <i>Gynecologic Oncology</i> , 2015, 136, 48-53.	1.4	79

#	ARTICLE	IF	CITATIONS
73	Sentinel Nodes in Cervical Cancer: Surgical Innovation Outside the Ivory Towers. <i>Annals of Surgical Oncology</i> , 2015, 22, 1759-1760.	1.5	2
74	Laparoscopic Supracervical Hysterectomy With Morcellation: Should It Stay or Should It Go?. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 185-192.	0.6	20
75	Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: Time to reconsider the FIGO staging system?. <i>Gynecologic Oncology</i> , 2015, 136, 269-273.	1.4	21
76	Radical trachelectomy in early-stage cervical cancer: A comparison of laparotomy and minimally invasive surgery. <i>Gynecologic Oncology</i> , 2015, 138, 585-589.	1.4	86
77	Challenges in the diagnosis and management of cervical neuroendocrine carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 805-810.	2.4	42
78	Overview of the Role of Imaging in Pelvic Exenteration. <i>Radiographics</i> , 2015, 35, 1286-1294.	3.3	13
79	Preventing Complications in Minimally Invasive Gynecologic Surgery. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 176-180.	0.8	1
80	Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation. <i>Gynecologic Oncology Reports</i> , 2014, 10, 28-29.	0.6	38
81	Patient Preferences for Side Effects Associated With Cervical Cancer Treatment. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1077-1084.	2.5	15
82	Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. <i>Gynecologic Oncology</i> , 2014, 135, 451-454.	1.4	37
83	Morbid Obesity as an Independent Risk Factor for Disease-Specific Mortality in Women With Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2014, 124, 1098-1104.	2.4	43
84	A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014, 132, 275-279.	1.4	25
85	Lymphadenectomy in Locally Advanced Cervical Cancer Study (LiLACS): Phase III Clinical Trial Comparing Surgical With Radiologic Staging in Patients With Stages IB2â€“IVA Cervical Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 3-8.	0.6	73
86	Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management. <i>Current Oncology Reports</i> , 2014, 16, 389.	4.0	133
87	Management of low-risk early-stage cervical cancer: Should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care?. <i>Gynecologic Oncology</i> , 2014, 132, 254-259.	1.4	172
88	A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014, 132, 366-371.	1.4	56
89	Sentinel Lymph Node Evaluation in Women with Cervical Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 540-545.	0.6	47
90	Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: A feasibility study. <i>Gynecologic Oncology</i> , 2014, 132, 149-153.	1.4	35

#	ARTICLE	IF	CITATIONS
91	Successful Laparoscopic Removal of Adnexal Mass in a Patient With a Large Ventral Hernia. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 325-326.	0.6	1
92	Physician pain and discomfort during minimally invasive gynecologic cancer surgery. <i>Gynecologic Oncology</i> , 2014, 134, 243-247.	1.4	45
93	Pelvic exenteration: Impact of age on surgical and oncologic outcomes. <i>Gynecologic Oncology</i> , 2014, 132, 114-118.	1.4	27
94	Analgesic and Antiemetic Requirements After Minimally Invasive Surgery for Early Cervical Cancer: A Comparison Between Laparoscopy and Robotic Surgery. <i>Annals of Surgical Oncology</i> , 2013, 20, 1355-1359.	1.5	33
95	Targeting Src and Tubulin in Mucinous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 6532-6543.	7.0	38
96	Unverifiable Accomplishments and Publications on Applications for Gynecologic Oncology Fellowships. <i>Obstetrics and Gynecology</i> , 2012, 119, 504-508.	2.4	7
97	Anatomic Location of PET-Positive Aortocaval Nodes in Patients with Locally Advanced Cervical Cancer: Implications for Surgical Staging. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1203-1207.	2.5	8
98	Utility of conization with frozen section for intraoperative triage prior to definitive hysterectomy. <i>Gynecologic Oncology</i> , 2012, 127, 307-311.	1.4	7
99	Triple injection lymphatic mapping technique to determine if parametrial nodes are the true sentinel lymph nodes in women with cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 467-471.	1.4	25
100	Metastatic adenocarcinoma found in inguinal, pelvic and para-aortic lymph nodes 14years following hysterectomy for adenocarcinoma in situ of the cervix. <i>Gynecologic Oncology Case Reports</i> , 2012, 2, 97-99.	0.9	2
101	Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. <i>Gynecologic Oncology</i> , 2012, 125, 241-244.	1.4	11
102	Quality of laparoscopic radical hysterectomy in developing countries: A comparison of surgical and oncologic outcomes between a comprehensive cancer center in the United States and a cancer center in Colombia. <i>Gynecologic Oncology</i> , 2012, 125, 326-329.	1.4	14
103	Conservative management of early stage cervical cancer: Is there a role for less radical surgery?. <i>Gynecologic Oncology</i> , 2011, 120, 321-325.	1.4	117
104	Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. <i>Gynecologic Oncology</i> , 2011, 123, 333-336.	1.4	118
105	Balancing Fertility and Oncologic Outcomes: Can We Have Our Cake and Eat It Too?. <i>Annals of Surgical Oncology</i> , 2011, 18, 10-11.	1.5	1
106	Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer. <i>Cancer</i> , 2011, 117, 1928-1934.	4.1	161
107	Minimally Invasive Surgical Approaches for Patients With Endometrial Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 226-234.	1.1	19
108	Targeting Src in Mucinous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 5367-5378.	7.0	42

#	ARTICLE	IF	CITATIONS
109	Primary Malignant Melanoma of the Vagina. <i>Obstetrics and Gynecology</i> , 2010, 116, 1358-1365.	2.4	105
110	Prevalence of Lymph Node Metastasis in Primary Mucinous Carcinoma of the Ovary. <i>Obstetrics and Gynecology</i> , 2010, 116, 269-273.	2.4	76
111	Microscopic Evaluation of Lymph-Node-Bearing Tissue in Early-Stage Cervical Cancer: A Dual-Institution Review. <i>Annals of Surgical Oncology</i> , 2010, 17, 1106-1110.	1.5	3
112	Unmasking the complexities of mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2010, 117, 491-496.	1.4	85
113	Conservative surgery in early-stage cervical cancer: What percentage of patients may be eligible for conization and lymphadenectomy?. <i>Gynecologic Oncology</i> , 2010, 119, 183-186.	1.4	34
114	Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2010, 119, 422-425.	1.4	28
115	Parametrial Involvement in Radical Hysterectomy Specimens for Women With Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2009, 114, 93-99.	2.4	174
116	Trends in laparoscopic and robotic surgery among gynecologic oncologists: A survey update. <i>Gynecologic Oncology</i> , 2009, 112, 501-505.	1.4	102
117	Sentinel Node Mapping in Vulvovaginal Melanoma Using SPECT/CT Lymphoscintigraphy. <i>Clinical Nuclear Medicine</i> , 2009, 34, 859-861.	1.3	37
118	Is Lymphatic Mapping in Uterine Cancer Feasible?. <i>Annals of Surgical Oncology</i> , 2008, 15, 1815-1817.	1.5	7
119	Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. <i>Gynecologic Oncology</i> , 2008, 108, 478-481.	1.4	58
120	Lymphatic mapping and sentinel lymph node detection in women with cervical cancer. <i>Gynecologic Oncology</i> , 2008, 110, S17-S20.	1.4	39
121	Laparoscopic and robotic techniques for radical hysterectomy in patients with early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2008, 110, S21-S24.	1.4	51
122	Laparoscopy training in gynecologic oncology fellowship programs. <i>Gynecologic Oncology</i> , 2008, 111, 197-201.	1.4	17
123	A Phase III Randomized Clinical Trial Comparing Laparoscopic or Robotic Radical Hysterectomy with Abdominal Radical Hysterectomy in Patients with Early Stage Cervical Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2008, 15, 584-588.	0.6	144
124	Radical Hysterectomy in Obese and Morbidly Obese Women With Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2008, 112, 899-905.	2.4	30
125	Ultrastaging Improves Detection of Metastases in Sentinel Lymph Nodes of Uterine Cervix Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1336-1343.	3.7	70
126	Lymphatic mapping and sentinel node biopsy in vulvar, vaginal, and cervical cancers. <i>Oncology</i> , 2008, 22, 529-36; discussion 538-9, 542-3.	0.5	6

#	ARTICLE	IF	CITATIONS
127	Comparison of Total Laparoscopic and Abdominal Radical Hysterectomy for Patients With Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2007, 110, 1174-1175.	2.4	4
128	Comparison of Total Laparoscopic and Abdominal Radical Hysterectomy for Patients With Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2007, 110, 96-102.	2.4	217
129	Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2007, 104, 100-103.	1.4	118
130	Total laparoscopic radical hysterectomy: Surgical technique and instrumentation. <i>Gynecologic Oncology</i> , 2007, 104, 13-16.	1.4	15
131	Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. <i>Gynecologic Oncology</i> , 2007, 104, 768-778.	1.4	64
132	Therapeutic value of pretherapeutic extraperitoneal laparoscopic staging of locally advanced cervical carcinoma. <i>Gynecologic Oncology</i> , 2007, 105, 304-311.	1.4	202
133	Current Perspectives on Lymphatic Mapping in Carcinomas of the Uterine Corpus and Cervix. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 471-478.	4.9	5
134	Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 1186-1193.	1.3	36
135	Electrothermal bipolar coagulation for pelvic exenterations. <i>Gynecologic Oncology</i> , 2006, 102, 534-536.	1.4	10
136	Fertility-sparing therapy for young women with endometrial cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 27-32.	2.4	14
137	Lymphatic mapping and sentinel node detection in gynecologic malignancies of the lower genital tract. <i>Current Oncology Reports</i> , 2005, 7, 435-443.	4.0	11
138	Quality of Life and Sexual Functioning in Cervical Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2005, 23, 7428-7436.	1.6	360
139	Characteristics of recurrence in patients who underwent lymphatic mapping for vulvar cancer. <i>Gynecologic Oncology</i> , 2004, 92, 205-210.	1.4	31
140	Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training. <i>Gynecologic Oncology</i> , 2004, 94, 746-753.	1.4	67
141	Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. <i>Gynecologic Oncology</i> , 2004, 95, 133-138.	1.4	309
142	Predictors of final histology in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2004, 95, 463-468.	1.4	133
143	Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer ¹ . <i>Journal of the American College of Surgeons</i> , 2004, 199, 388-393.	0.5	132
144	Impact of timing of urinary catheter removal on voiding dysfunction after radical hysterectomy for early cervical cancer. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003654.	2.5	1